Clinical • Enrollment closed • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849 • self-amplifying RNA cancer vaccine